BACKGROUND: Consumption of fish and n-3 (omega-3) long-chain polyunsaturated fatty acids (LCPUFAs) has been associated with reduced risk of coronary artery disease (CAD) mortality. OBJECTIVE: The aim was to examine the relation between dietary intake of n-3 LCPUFAs or fish and risk of future coronary events or mortality in patients with well-characterized CAD. DESIGN: This was a substudy of 2412 participants in the Western Norway B Vitamin Intervention Trial with a median follow-up time of 57 mo. Patients aged >18 y diagnosed with CAD (81% men) completed a food-frequency questionnaire at baseline, from which daily intakes of eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids as well as fish were estimated on the basis of diet and intakes of supplements including fish and cod liver oils. The main endpoint was a composite of coronary events, including coronary death, nonfatal acute myocardial infarction, and unstable angina pectoris. RESULTS: The mean (+/-SD) intakes of n-3 LCPUFAs in quartiles 1-4 were 0.58 +/- 0.29, 0.83 +/- 0.30, 1.36 +/- 0.44, and 2.64 +/- 1.18 g/d, respectively. We found no dose-response relation between quartiles of n-3 LCPUFAs (based on intake as percentage of total energy) or fish and coronary events or separate endpoints. A post hoc additive proportional hazards model showed a slightly increased risk of coronary events at an intake of n-3 LCPUFAs < approximately 0.30 g/d. CONCLUSION: Among Norwegian patients with CAD consuming relatively high amounts of n-3 LCPUFAs and fish, there were no significant trends toward a reduced risk of coronary events or mortality with increasing intakes. This trial was registered at clinicaltrials.gov as NCT00354081.
BACKGROUND: Consumption of fish and n-3 (omega-3) long-chain polyunsaturated fatty acids (LCPUFAs) has been associated with reduced risk of coronary artery disease (CAD) mortality. OBJECTIVE: The aim was to examine the relation between dietary intake of n-3 LCPUFAs or fish and risk of future coronary events or mortality in patients with well-characterized CAD. DESIGN: This was a substudy of 2412 participants in the Western Norway B Vitamin Intervention Trial with a median follow-up time of 57 mo. Patients aged >18 y diagnosed with CAD (81% men) completed a food-frequency questionnaire at baseline, from which daily intakes of eicosapentaenoic, docosapentaenoic, and docosahexaenoic acids as well as fish were estimated on the basis of diet and intakes of supplements including fish and cod liver oils. The main endpoint was a composite of coronary events, including coronary death, nonfatal acute myocardial infarction, and unstable angina pectoris. RESULTS: The mean (+/-SD) intakes of n-3 LCPUFAs in quartiles 1-4 were 0.58 +/- 0.29, 0.83 +/- 0.30, 1.36 +/- 0.44, and 2.64 +/- 1.18 g/d, respectively. We found no dose-response relation between quartiles of n-3 LCPUFAs (based on intake as percentage of total energy) or fish and coronary events or separate endpoints. A post hoc additive proportional hazards model showed a slightly increased risk of coronary events at an intake of n-3 LCPUFAs < approximately 0.30 g/d. CONCLUSION: Among Norwegian patients with CAD consuming relatively high amounts of n-3 LCPUFAs and fish, there were no significant trends toward a reduced risk of coronary events or mortality with increasing intakes. This trial was registered at clinicaltrials.gov as NCT00354081.
Authors: Eli Skeie; Elin Strand; Eva R Pedersen; Bodil Bjørndal; Pavol Bohov; Rolf K Berge; Gard F T Svingen; Reinhard Seifert; Per M Ueland; Øivind Midttun; Arve Ulvik; Steinar Hustad; Christian A Drevon; Jesse F Gregory; Ottar Nygård Journal: PLoS One Date: 2015-06-03 Impact factor: 3.240
Authors: Léopold K Fezeu; François Laporte; Emmanuelle Kesse-Guyot; Valentina A Andreeva; Jacques Blacher; Serge Hercberg; Pilar Galan Journal: PLoS One Date: 2014-04-07 Impact factor: 3.240
Authors: Heidi Borgeraas; Elin Strand; Eva Ringdal Pedersen; Jutta Dierkes; Per Magne Ueland; Reinhard Seifert; Eirik Rebnord Wilberg; Pavol Bohov; Rolf K Berge; Dennis W T Nilsen; Ottar Nygård Journal: Cardiol Res Pract Date: 2012-12-31 Impact factor: 1.866
Authors: Elin Strand; Eva R Pedersen; Gard F T Svingen; Hall Schartum-Hansen; Eirik W Rebnord; Bodil Bjørndal; Reinhard Seifert; Pavol Bohov; Klaus Meyer; J Kalervo Hiltunen; Jan E Nordrehaug; Dennis W T Nilsen; Rolf K Berge; Ottar Nygård Journal: BMC Med Date: 2013-10-08 Impact factor: 8.775